Japan market is very different as Temcell is on the market based on safety data only (unique to Japan) which allows safe treatments to be used by patients ahead of full approval.
As such uptake is significantly slower as it is pretty much driven by word of mouth/ recommendations from practitioners.
Seeing revenues double two quarters in a row is encouraging and a sign that the word is spreading.
US launch will be FDA approved and can be rolled out and marketed for its efficacy and safety which will lead to a must faster uptake/market penetration. Not to mention the patient population is significantly higher in the US.
Ann: Mesoblast Reports on Annual and Fourth Quarter Results, page-22
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |